Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Rating of “Moderate Buy” by Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has been given a consensus rating of “Moderate Buy” by the fifteen research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $42.2143.

VRDN has been the subject of several recent analyst reports. Truist Financial cut their price objective on Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Royal Bank Of Canada decreased their price target on shares of Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating on the stock in a report on Friday, February 27th. UBS Group began coverage on shares of Viridian Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $50.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Finally, Wedbush reiterated an “outperform” rating and set a $44.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, March 11th.

Insider Buying and Selling

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.58% of the stock is owned by insiders.

Institutional Trading of Viridian Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd bought a new position in shares of Viridian Therapeutics during the third quarter valued at about $35,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $36,000. Farther Finance Advisors LLC grew its holdings in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Larson Financial Group LLC purchased a new position in shares of Viridian Therapeutics in the third quarter worth $52,000.

Viridian Therapeutics Price Performance

VRDN stock opened at $26.98 on Friday. The firm has a 50 day moving average of $30.24 and a 200-day moving average of $27.48. The firm has a market capitalization of $2.76 billion, a P/E ratio of -8.20 and a beta of 1.00. Viridian Therapeutics has a 12 month low of $9.90 and a 12 month high of $34.29. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08.

Viridian Therapeutics (NASDAQ:VRDN) last posted its earnings results on Thursday, February 26th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. As a group, sell-side analysts predict that Viridian Therapeutics will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.